SOURCE: Proteonomix


June 16, 2011 09:00 ET

Proteonomix, Inc. (PROT) Engages Investment Banking Firm

MOUNTAINSIDE, NJ--(Marketwire - Jun 16, 2011) - PROTEONOMIX, INC. (OTCBB: PROT), a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives, announced today that it has engaged the services of Bedminster Financial Group, Ltd. to provide investment banking services for the Company with a view to finding joint venture partners and/or strategic investments into one or more of its subsidiaries in order to advance the scientific and commercial development of the subsidiaries and the technologies possessed by the subsidiaries.

Michael Cohen, President of the Company, stated: "Proteonomix subsidiaries have licensed several technologies, including but not limited to Thor BioPharma, a subsidiary of Proteonomix, which has licensed the UMK-121 technology; Proteoderm which has licensed the cosmeceutical and skin-regeneration technologies as well as Proteonomix which has cell platform technologies and licenses; StromaCel, Inc. which has licensed therapeutic technologies for the treatment of Cardiovascular Disease (CVD). The Company's goal is to find the proper suitors to advance and expedite the advancement of its technologies. We have begun negotiations with several companies."

About Proteonomix, Inc.:
Proteonomix is a biotechnology company focused on developing therapeutics based upon use of human cells and their derivatives. The Proteonomix Family of companies includes Proteoderm, StromaCel, National Stem Cell, PRTMI, The Sperm Bank of New York and THOR BioPharma. Proteoderm, Inc. is wholly owned subsidiary that has developed an anti-aging line of skin care products. StromaCel, Inc. develops therapeutic modalities for the treatment of Cardiovascular Disease (CVD). National Stem Cell, Inc. is Proteonomix's subsidiary. The Sperm Bank of New York, Inc. is a fully operational tissue bank. Proteonomix Regenerative Translational Medicine Institute, Inc. ("PRTMI") intends to focus on the translation of promising research in stem cell biology and cellular therapy to clinical applications of regenerative medicine. Proteonomix intends to create and dedicate a subsidiary to each of its technologies. Please also visit,, and

Forward-looking statements:
Certain statements contained herein are "forward-looking statements" (as defined in the Private Securities Litigation Reform Act of 1995). Proteonomix, Inc. cautions that statements made in this press release constitute forward-looking statements and makes no guarantee of future performance. Actual results or developments may differ materially from projections. Forward-looking statements are based on estimates and opinions of management at the time statements are made.

Contact Information